<DOC>
	<DOCNO>NCT02880670</DOCNO>
	<brief_summary>This open-label , single-dose , study healthy male . The primary objective ass pharmacokinetics ( PK ) , metabolism , rout elimination single oral dose radiolabeled BMS-986142 healthy male subject .</brief_summary>
	<brief_title>Pharmacokinetics Metabolism Study Radiolabeled BMS-986142 Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Signed Informed Consent Target population : Healthy male clinically significant deviation normal medical history , physical examination , vital sign , electrocardiogram ( ECGs ) , physical measurement , clinical laboratory test Body weight least 50 kilogram ( 110 pound ) ; body mass index ( BMI ) 18 32 kg/m2 . History chronic acute illness include active TB last 3 year , recent infection , gastrointestinal disease , smoke within less 6 month prior dose , alcohol abuse , inability tolerate oral medication , inability venipunctured . Vaccination plan vaccination live vaccine 12 week prior first dose study drug , course study , 30 day last dose study drug . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , electrocardiogram , clinical laboratory determination beyond consistent target population . History allergy adverse drug reaction oral contraceptive compound Bruton tyrosine kinase ( BTK ) inhibitor . Participated radiolabeled drug study within previous 12 month ; clinically significant diagnostic therapeutic radiation exposure within previous 12 month ; current employment job require radiation exposure monitoring .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rheumatoid</keyword>
</DOC>